Piper Sandler downgraded Point Biopharma (PNT) to Neutral from Overweight with an unchanged price target of $12.50 to reflect the shares trading above Eli Lilly’s (LLY) $12.50 per share acquisition price.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PNT:
- Eli Lilly (NYSE:LLY) Jumps on Analyst Optimism
- Point Biopharma downgraded to Market Perform from Outperform at Leerink
- Point Biopharma downgraded to Market Perform from Outperform at Raymond James
- Point Biopharma downgraded to Hold from Buy at Truist
- Lantheus program validated by Point Biopharma buyout, says Mizuho